• Peter Morsing, Vaccinogen Chief Operating Officer

Chief Operating Officer

Peter Morsing, Ph.D. is Chief Operating Officer for Vaccinogen, Inc.  He was promoted to the position in November 2015 after joining the company as its Global Head of Business Development & Strategy in January 2015.

As COO, Dr. Morsing oversees Vaccinogen’s clinical, logistical, manufacturing and business development activities, and manages the company’s Ireland Research Centre in Dublin.  Importantly, Dr. Morsing is responsible for managing Vaccinogen’s ACTIVE Phase IIIb OncoVAX® clinical trial, the expansion of its human antibody program (HuMabs), and the integration of DiCAST, the revolutionary high-throughput, multiplex, analysis platform which Vaccinogen recently negotiated an exclusive option agreement to acquire from Dublin City University.

Previously, as Vaccinogen’s Global Head of Business Development & Strategy, Dr. Morsing led internal and external efforts designed to build value behind Vaccinogen’s assets while targeting opportunities to enhance the company’s growth potential.  Among his many accomplishments, Dr. Morsing was instrumental in pursuing and securing the option agreement for DiCAST and establishing the Company’s Ireland Research Centre.

Dr. Morsing has nearly 20 years of business and drug development experience focusing on cardiovascular and metabolic diseases. In his previous role as Search and Evaluation Director with AstraZeneca, he was responsible for identification and evaluation of novel therapeutic approaches to treating cardiovascular and metabolic diseases and led the development of licensing opportunities to bring project leads from initial negotiations to completion. Prior to that, Dr. Morsing served as Evaluation Director, Strategy and Externalization for AstraZeneca, where his core responsibilities included exploring new potential strategic areas within CVMD, developing strategy for renal complications, identifying new indications for existing clinical assets and creating a portfolio-based approach for opportunities in chronic heart failure and renal disease.

As Licensing Director, Strategic Partnering and Business Development, AstraZeneca, Dr. Morsing was team leader for the evaluation of external cardiovascular opportunities specializing in diabetes and obesity. His responsibilities included identification of licensing candidates, securing contracts with external companies and scientific, commercial and financial evaluation leading to launch development plans.

In addition to his work in cardiovascular and metabolic disease research and development, Dr. Morsing also served as Portfolio Manager for the Second Swedish National Pension Fund where he was responsible for evaluating and managing investments in the pharmaceutical and biotechnology sectors.

He holds a Ph.D. in Medical Science from Lund University in Sweden and has held several academic appointments including Professor of Physiology at Gothenburg University, Associate Professor at the University of North Carolina at Chapel Hill and Associate Professor of Physiology, Lund University. He also served as a Postdoctoral Fellow at Yale University.